Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSKIRA-4 MRI Sub-Study
NCT02092961Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Feb 2011
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of fostamatinib in rheumatoid arthritis (RA) (3 arms), sponsored by AstraZeneca. Primary endpoint: OMERACT RAMRIS Synovitis Score at 6 weeks. Started Feb 2011; status: terminated.
02
Drugs
fostamatinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02092961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02092961.